EUDALDO APONTE III: Open Payments
NPI 1720450166 · HIALEAH, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$33,572 in 92 payments from 11 companies in 2025. Trend: 2023 $63,314 · 2024 $33,852 · 2025 $33,572
Speaker / faculty: $30,041Food & beverage: $2,448Travel & lodging: $753Consulting: $330
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 23 | $18,008 |
| ABBVIE INC. | 30 | $14,440 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $273 |
| Alkermes, Inc. | 7 | $264 |
| Neurocrine BioSciences, Inc. | 8 | $214 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $176 |
| E.R. Squibb & Sons, L.L.C. | 3 | $67 |
| Bausch Health US, LLC | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
Products named: AUSTEDO XR, VRAYLAR, CAPLYTA, LYBALVI, INGREZZA, TRINTELLIX, COBENFY, APLENZIN.
Industry payments across FL — which companies pay providers there.
